Stock Information
symbol line chart

ANROAlto Neuroscience Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Amit Etkin

Location

California, USA

Exchange

NYSE

Website

https://www.altoneuroscience.com

Summary

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.

Company Info

CEO

Amit Etkin

Location

California, USA

Exchange

NYSE

Website

https://www.altoneuroscience.com

Summary

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.

AI Insights for ANRO
3 min read

Quick Summary

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing personalized psychiatric and neurological therapies. The company’s mission is to use neurobiology, biomarkers, and patient-selection tools to create more effective treatment options for patients with mental-health and brain-related disorders. It does not currently report operating revenue, which indicates that its business is still centered on research, clinical development, and future commercialization rather than product sales. Its potential future customers include psychiatrists, neurologists, hospitals, specialty clinics, managed-care organizations, government payers, and patients with conditions such as depression, bipolar depression, treatment-resistant depression, and Parkinson’s disease-related symptoms. The company is headquartered in Los Altos, California, and is led by CEO Amit Etkin. Because Alto is clinical-stage, investors are primarily valuing its drug pipeline, trial design, scientific platform, cash runway, and probability of regulatory success rather than current earnings.

The Bull Case

  • Alto’s primary strength is its focus on precision psychiatry, an area with significant unmet medical need and limited personalization in current practice.
  • The company’s strategy of leveraging neurobiology and patient-selection methods may help improve the probability of detecting treatment effects in clinical trials.
  • Its pipeline now includes multiple programs across depression, treatment-resistant depression, bipolar depression, and Parkinson’s-related opportunities.
  • The acquisition of Chase Therapeutics’ portfolio gives Alto an additional clinical-stage asset with early human data and a potentially pivotal Phase 2b path.
  • The company also operates in markets where existing therapies often have tolerability issues, delayed onset, incomplete response, or poor adherence.

The Bear Case

  • Alto’s biggest weakness is that it has no current operating revenue and remains dependent on external capital or existing cash resources to fund development.
  • The company is loss-making, with negative net income and negative EPS, which is common for clinical-stage biotech but still creates dilution and financing risk.
  • Its pipeline assets remain investigational, so there is no guarantee of regulatory approval or future commercial sales.
  • The recent ALTO-207 data came from a small 32-patient Phase 2a trial, which may not predict success in a larger and more rigorous Phase 2b study.
  • Psychiatry trials are particularly difficult because placebo response, heterogeneous patient populations, subjective endpoints, and adherence issues can complicate results.

Key Risks

  • Alto faces significant clinical, regulatory, financial, and competitive risks.
  • The most important risk is clinical failure, because negative or inconclusive trial results could sharply reduce the value of the company’s pipeline.
  • Regulatory agencies may require larger, longer, or more expensive trials than expected, especially in complex psychiatric indications.
  • The company’s lack of revenue means it may need to raise additional capital, which could dilute shareholders if market conditions are unfavorable.

What to Watch

UpcomingDuring the most recent reported period, Alto remained a clinical-stage company with no operating revenue and continued operating losses.
UpcomingThe company reported total revenue of zero, total gross profit of zero, total operating income of approximately negative $27.1 million, and net income of approximately negative $26.2 million.
UpcomingThe most important recent strategic event was the acquisition of Chase Therapeutics’ dopamine agonist drug-combination portfolio.
ExpectedIn the next quarter, investors are likely to watch for additional details on Alto’s development plans for ALTO-207 and ALTO-208.

Price Drivers

  • ANRO’s stock price is primarily driven by clinical-trial expectations, pipeline updates, acquisition news, and investor sentiment toward clinical-stage biotechnology companies.
  • The company has no reported revenue, negative earnings, negative net income, and a basic EPS of -0.8, so traditional valuation metrics such as price-to-earnings are not useful.
  • Investors are likely focused on the probability that ALTO-100, ALTO-207, ALTO-208, or other programs can generate positive trial data and eventually reach approval.
  • The recent acquisition of Chase Therapeutics’ dopamine-agonist portfolio is a notable catalyst because it adds a treatment-resistant depression program with planned Phase 2b development.

Recent News

  • Alto Neuroscience recently acquired Chase Therapeutics’ dopamine agonist drug-combination portfolio for treatment-resistant depression and Parkinson’s disease.
  • The deal included a $1.75 million upfront payment and up to $71.5 million in potential milestone payments to Chase Therapeutics.
  • The lead acquired asset, ALTO-207, combines pramipexole with ondansetron and showed significant depression-symptom improvement in a small Phase 2a trial.
  • Alto plans to begin a potentially pivotal Phase 2b trial in treatment-resistant depression by mid-2026, with data expected in 2027.

Market Trends

  • The broader market for psychiatric and neurological therapies is being shaped by rising diagnosed prevalence, improved diagnostics, and persistent unmet need.
  • In bipolar depression, market forecasts point to growth across the United States, Europe, the United Kingdom, and Japan from 2026 through 2036.
  • Existing treatments such as lithium, valproate, quetiapine, lurasidone, VRAYLAR, and FANAPT help many patients but still leave gaps related to relapse, side effects, delayed diagnosis, and adherence.
  • This environment creates room for new therapies that offer better efficacy, tolerability, speed of onset, or patient matching.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on ANRO

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@IsabelLynn 1 month ago

Checking out Alto Neuroscience

Checking out Alto Neuroscience

i've been following the progress at Alto Neuroscience lately because their work in precision psychiatry looks pretty promising. the movement we've seen with has caught my eye, and i'm wondering if you guys think this rally has more room to run. what are your thoughts on their upcoming clinical data?

No more topics to show